The Medical Letter on Drugs and Therapeutics
Abemaciclib (Verzenio) - A Third CDK 4/6 Inhibitor for Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved abemaciclib (Verzenio – Lilly), an oral cyclin-dependent kinase (CDK) 4/6 inhibitor, for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Abemaciclib is the third CDK 4/6 inhibitor to be approved in the US for this indication.

MECHANISM OF ACTION — CDKs 4 and 6 regulate the G1/S phase transition within the cell cycle; they are often overexpressed in HR-positive breast cancer, leading to cell cycle progression and cellular proliferation. Inhibition of CDK 4/6 results in cell cycle arrest, senescence, and apoptosis.

CLINICAL STUDIES — In a single-arm trial (MONARCH 1), 132 women with HR-positive, HER2-negative metastatic breast cancer that had progressed on or after endocrine therapy and had been treated with one or two chemotherapy regimens for metastatic ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Abemaciclib (Verzenio) - A Third CDK 4 6 Inhibitor for Breast Cancer
Article code: 1533e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian